Glenmark's Ryaltris nasal spray, already approved in the US, EU and other markets, has now secured China's NMPA approval, strengthening its global respiratory portfolio
Glenmark Pharmaceuticals Ltd on Monday said its arm Glenmark Specialty SA has received approval from China's National Medical Products Administration for the nasal spray RYALTRIS used to treat allergic rhinitis. The National Medical Products Administration (NMPA) of China has approved RYALTRIS Compound Nasal Spray (GSP 301 NS) for the treatment of allergic rhinitis (AR) in adults and children -- specifically for treatment of moderate to severe seasonal AR in adults and pediatric patients 6 years of age and older, and moderate to severe perennial AR in adults and pediatric patients 12 years of age and older, the company said in a statement. The approval granted with zero supplementation requests is an important milestone in Glenmark's respiratory pipeline and reflects continued progress in advancing innovative and differentiated therapies for patients with chronic conditions, it added. "The approval of RYALTRIS in China is a significant step in expanding our specialty respiratory ...
From skin rashes to seizures, here's how to spot adverse drug reactions early and protect yourself with timely medical action
If workouts, hot showers, or even nervous moments leave you with itchy hives, you may have cholinergic urticaria, often known as sweat allergy; doctors explain causes, triggers and treatments
Delhi's Sir Ganga Ram hospital has established a link between prolonged exposure to pigeons and severe lung diseases
To manage allergies and lift your body's guards for an allergy-free life, focus around what you eat. Remembering nutrient-rich food sources in your daily diet can help you better your immune system
Glenmark Pharma on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.
The recommendation all but assures the agency will approve the drug, called Palforzia and made by Aimmune Therapeutics
Our overuse of antibiotics and C-sections affects the set of organisms called the microbiome that an infant is exposed to growing up
People can get asthma from allergies and that can be very dangerous if it's left untreated